Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:e728-e732
doi: 10.1161/CIRCULATIONAHA.105.601492
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lucas, A. R.
Right arrow Articles by Pepine, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucas, A. R.
Right arrow Articles by Pepine, C. J.
Related Collections
Right arrow Other diabetes
Right arrow Other Treatment
Right arrow Acute coronary syndromes
Right arrow Other Stroke Treatment - Medical
Right arrow Platelets
Right arrowRelated Article

(Circulation. 2006;113:e728-e732.)
© 2006 American Heart Association, Inc.


Clinician Update

Inflammation in Atherosclerosis

Some Thoughts About Acute Coronary Syndromes

Alexandra R. Lucas, MD; Renee Korol, MSc; Carl J. Pepine, MD

From Robarts Research Institute (A.R.L.), and Division of Cardiology, Department of Medicine (A.R.L.) and Department of Medical Biophysics (A.R.L., R.K.), University of Western Ontario, London, Ontario; and Division of Cardiovascular Medicine, University of Florida, Gainesville (C.P.).

Correspondence to Alexandra Lucas, MD, Robarts Research Institute, 100 Perth Dr, PO Box 5015, London, Ontario, Canada N6A 2K8 (e-mail arl@robarts.ca); after July 1, 2006, c/o Linda H. Horne, Assistant to Dr Carl Pepine, Division of Cardiovascular Medicine, 1600 SW Archer Rd, Box 100277, Gainesville, FL 32610–0277.


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The innate or natural immune response is the body’s rapid first line of defense for environmental threats (eg, trauma and infection), responding long before an immune defense is mounted.1,2 This response involves a series of reactions that have evolved to limit damage, isolate pathogens (noxious agents), and initiate repair processes. Cells distinguish between pathogen and self by using signals from pattern-recognition receptors, scavenger receptors (CD-36, SR-A), and Toll-like receptors (TLRs) on macrophage and dendritic cells.2 These receptors recognize pathogen-associated patterns in nucleic acids, proteins, carbohydrates, and lipids. Flow-dependent regulation of TLR2 surface expression in endothelial cells and ligation of TLR1, TLR2, and TLR4 in plaque result in recruitment of adaptor protein myeloid differentiation factor 88, followed by activation of nuclear factor-{kappa}B and mitogen-activated protein kinases.1–4 This results in a cascade of proinflammatory molecules such as interleukin (IL)-6 that drive C-reactive protein (CRP) production, chemokines that act as chemoattractants, and serine proteases that drive thrombosis, all of which contribute to inflammation and pathogen clearance.

Accumulating evidence supports a central role for inflammation in preclinical atherosclerosis, with acute coronary syndrome (ACS) as a principle clinical expression.4 Indeed, ACS, ischemic brain syndrome (stroke/transient ischemic attack), and peripheral arterial occlusion1–4 result from a chronic inflammatory process, as well as disorders of lipid metabolism, modified by genetic and environmental factors. Arterial wall function and structure are modulated by interactions between injurious agents, blood vessel wall elements and monocytes, T lymphocytes, and platelets. Invading mononuclear cells release enzymes (eg, matrix metalloproteinases [MMPs]) that degrade collagen . . . [Full Text of this Article]


Related Article:

Issue Highlights
Circulation 2006 113: 2031. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Ther Adv Cardiovasc DisHome page
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon
Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
P. K. Cheruvu, A. V. Finn, C. Gardner, J. Caplan, J. Goldstein, G. W. Stone, R. Virmani, and J. E. Muller
Frequency and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaques in Human Coronary Arteries: A Pathologic Study
J. Am. Coll. Cardiol., September 4, 2007; 50(10): 940 - 949.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
A. Esmaillzadeh, M. Kimiagar, Y. Mehrabi, L. Azadbakht, F. B. Hu, and W. C. Willett
Dietary Patterns and Markers of Systemic Inflammation among Iranian Women
J. Nutr., April 1, 2007; 137(4): 992 - 998.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Libby and P. M. Ridker
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46.
[Abstract] [Full Text] [PDF]